drugset / Trial / NCT00002393

A Study of Indinavir Taken With or Without DMP 266

NCT00002393

Phase 3 Completed 300 enrolled Dupont Merck
Parallel-groupTreatment

Summary

The purpose of this study is to see if it is safe and effective to add DMP 266 to an anti-HIV treatment program of indinavir and nucleoside reverse transcriptase inhibitors (NRTIs).

Timeline

Start
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Background Efavirenz Other / unclassified
Background INDINAVIR ANHYDROUS Other / unclassified